The proprietary Trenzyme ExoIN system makes use of a protein fusion approach. The ExoIN polyprotein is co-translationally processed to the respective free proteins by endogenous proteases in every eukaryotic cell. 

The hall-mark of this strategy is that all cells expressing the selectable marker must co-express the target protein. Furthermore, due to the fact that biological systems always take the path of least resistance, all cells express the target protein homogenously at a given selection pressure. Consequently, the target expression can be modulated by applying different strength of selection according to the needs of the biological application of the stable cell line.

In contrast, virtually all competitor strategies to develop mammalian cell lines involve vectors, where the target protein expression is not directly linked to the expression of the selectable marker. At most, the marker and the target are encoded on the same mRNA but then independently translated (e.g. IRES based polycistronic vectors). That means that in many cases, only a minor fraction of stably transfected mammalian cells show satisfying target expression.

• Homogenous recombinant expression within the entire stable pool in as little as 3 days
• Therefore rapid PoC in 1 week
• Stable homogenous cell line within 2 weeks
• No need for clonal cell line
• Tunable expression
• Works with any cell line and target

Watch the video to learn how the ExoIN system works!